The timeline varies based on individual factors including starting weight, presence of sleep apnea, and sensitivity to the medication adjustment period
Whole Body Overall metabolic improvements: Insulin sensitivity cells use insulin more effectively Muscle fat infiltration less fat stored in muscle Subcutaneous, abdominal, and visceral fat reduces unhealthy fat deposits
Wegovy is a once weekly prescription medication containing semaglutide, which is used for chronic weight management in adults with obesity or overweight who also have weight-related health conditions, such as insulin resistance, high blood pressure, or high cholesterol
This form is intended for the insurer to collect evidence that Wegovy is medically necessary for you
Importantly, this heterogeneity is not limited to the magnitude of weight loss, but may also include minimal treatment response, persistent appetite, weight regain, and, in rare cases, paradoxical increases in appetite and food intake
